CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, a biotechnology company creating novel, context-dependent medicines for cancer, today announced that Barbara Weber, M.D., has been named the company’s full-time Chief Executive Officer. Dr. Weber will transition from her current role as interim Chief Executive Officer of Tango, and will continue as a Venture Partner at Third Rock Ventures.
Dr. Weber brings more than 25 years of experience in senior leadership roles at organizations focused on translating emerging genetic insights into novel drug development strategies. At Third Rock Ventures she helped to establish Tango and Relay Therapeutics, and served as interim Chief Medical Officer at Neon Therapeutics. Previously, she held senior leadership positions at Novartis and GlaxoSmithKline, and was a distinguished academic researcher focused on cancer genetics at the Perelman School of Medicine, University of Pennsylvania. A detailed biography is available here.
“We are thrilled that Barb will transition to full-time CEO at Tango, building on the tremendous work she has done to help create and nurture the company, attract a stellar team, and develop a strong product engine,” said Alexis Borisy, partner at Third Rock Ventures and chairman of the Tango Board of Directors. “Barb’s deep insights and pioneering work in cancer genetics, coupled with her vast drug development and management experience, make her the perfect fit for leading Tango over the long term.”
Tango Therapeutics was launched in March 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that will provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango’s programs are focused on the area of synthetic lethality, the interaction between two genes that causes cell death when both are inactivated.
“We are making strong early progress in validating the premise upon which Tango was founded, and in building the team and culture that will allow us to have a sustainable impact,” Dr. Weber said. “The insights and technologies now available to us have unlocked vast new areas of drug development that were out of reach only a few years ago. I am thrilled to have the opportunity to lead the talented team at Tango as we work together, pioneering a promising new approach for patients.”
About Tango Therapeutics
Tango Therapeutics is a biotechnology company developing novel medicines for patients by discovering and drugging context-dependent vulnerabilities in cancers. Tango was launched in 2017 by Third Rock Ventures and is headquartered in Cambridge, Mass. For more information, please visit www.tangotx.com.
About Third Rock Ventures
Third Rock Ventures is a leading healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people’s lives. By combining our team’s scientific vision, strategic leadership, operational expertise and innovative deal-making capabilities, we nurture bold ideas that translate into successful business enterprises. Recognizing that the best way to create value for our investors is to create value for patients, our companies are built on a solid foundation of science, medicine, people and business strategy. For more information, please visit www.thirdrockventures.com.